Bevacizumab in patients with metastatic colorectal cancer at the Colombian National Cancer Institute: A case series study
Keywords:
Colorectal neoplasm, bevacizumab, monoclonal antibodiesAbstract
Objectives: To describe the clinical and epidemiolgical features of patients with metastatic colon cancer treated with bevacizumab at the National Cancer Institute of Colombia (NCI).
Methods: Review was undertaken on 38 clinical cases of patients diagnosed for metastatic colorectal cancer and treated at the NCI Oncology Clinic from 2010 to 2011.
Results: Median patient age when treated with bevacizumab was 57 years; most frequent metastatic sites were the liver and peritoneum. Most commonly used chemotherapy regimen with bevacizumab included 5 fluoruracil/leucovorin and FOLFOX. Bevacizumab was generally well tolerated, with few adverse events
Author Biographies
Juan Andrés Rubiano, Instituto Nacional de Cancerología
Grupo de Oncología Clínica, Instituto Nacional de Cancerología, Bogotá, D. C., Colombia.
Alejandro Garrido, Instituto Nacional de Cancerología
Grupo de Oncología Clínica, Instituto Nacional de Cancerología, Bogotá, D. C., Colombia.
Juan Sebastián Castillo, Instituto Nacional de Cancerología
Grupo de Oncología Clínica, Instituto Nacional de Cancerología, Bogotá, D. C., Colombia.
Grupo de Investigación Clínica, Instituto Nacional de Cancerología, Bogotá, D. C., Colombia.
References
Boyiadzis M, Foon KA. Approved monoclonal antibodies for cancer therapy. Expert Opin Biol Ther. 2008;8:1151-8.
https://doi.org/10.1517/14712598.8.8.1151
Köhne CH, Lenz HJ. Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer. Oncologist. 2009;14:478-88.
https://doi.org/10.1634/theoncologist.2008-0202
Wagner A, Arnold D, Grothey A, Haerting J, Unverzagt S. Anti-angiogenic therapies for metastatic colorectal cancer (Review). Cochrane Database Syst Rev. 2009:CD005392.
https://doi.org/10.1002/14651858.CD005392.pub3
Ellis LM. Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal cancer. Semin Oncol. 2006;33(5 Suppl 10):S1-7.
https://doi.org/10.1053/j.seminoncol.2006.08.002
Puthillath A, Patel A, Fakih MG. Targeted therapies in the management of colorectal carcinoma: role of bevacizumab. OncoTargets Ther. 2009;2:1-15.
https://doi.org/10.2147/OTT.S3026
Instituto Nacional de Cancerología (INC). Atlas de mortalidad por cáncer en Colombia. Bogotá: INC; 2009.
Instituto Nacional de Cancerología (INC). Anuario estadístico. Bogotá: INC; 2009.
Hurwitz H, Fehrenbacher L, Novotny W. bevacizumab plus irinotecan, fluorouracil and leucovorin for metastasic colorectal cancer. N Engl J Med. 2004;350:2335-42.
https://doi.org/10.1056/NEJMoa032691
Hochster S, Hart L, Ramanathan R. Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): final analysis of the TREE-Study. Proc Am Soc Clin Oncol. 2006;24:148s.
Sobrero A, Ackland S, Clarke S. Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer. Oncology. 2009;77:113-9.
https://doi.org/10.1159/000229787
Giantonio B, Catalano P, Meropol N. Bevacizumab in combination with oxaliplatin, fluoracil, and leucovorin (FOLFOX 4) for previously treated metastasic colorectal cancer: results from Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25:1539-44.
https://doi.org/10.1200/JCO.2006.09.6305
Cao Y, Tan A, Gao F, Liu L, Liao C, Mo Z. A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer. Int J Colorectal Dis. 2009;24:677-85.
https://doi.org/10.1007/s00384-009-0655-9
Welch S, Spithoff K, Rumble R, Maroun J. bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review. Ann Oncol. 2010;21:1152-62.
https://doi.org/10.1093/annonc/mdp533
Kozloff M, Yood M, Berlin J, Flynn P, Kabbinavar F. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist. 2009;14:862-70.
https://doi.org/10.1634/theoncologist.2009-0071
Van Cutsem E, Rivera F, Berry S, Kretzschmar A, Michael M, DiBartolomeo M. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol. 2009;20:1842-7.
How to Cite
Downloads
Downloads
Published
Issue
Section
License
Todos los derechos reservados.
